{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:21:53Z","timestamp":1774272113316,"version":"3.50.1"},"reference-count":47,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"La Fondation Ernest Boninchi","award":["No Number"],"award-info":[{"award-number":["No Number"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Thoracic tumors, including lung adenocarcinoma (LUAD) and malignant pleural mesothelioma (MM), remain a leading cause of cancer-related deaths, primarily due to the challenges in treating advanced thoracic tumors. New drugs with optimal efficacy and minimal side effects are required. Traditional Chinese Medicine (TCM) compounds offer a promising alternative. Our study explores the effectiveness of the TCM compound Narciclasine against LUAD and MM. Spheroids derived from LUAD (A549, LuCa1) and MM (MSTO-211H, H2052\/484) cell lines were treated with Narciclasine, and efficacy was evaluated through cell morphology analysis, intracellular adenosine triphosphate (ATPi) and lactate dehydrogenase (LDH) assays, RT-qPCR, and western blot analysis. Narciclasine reduced cell viability, with an 80% reduction in viability in MM. It induced cell apoptosis and inhibited proliferation. The IC50 values for Narciclasine ranged from 50 to 150 nM. In silico analysis identified shared gene targets between Narciclasine, LUAD, and MM. Narciclasine modulated the expression of genes associated with ferroptosis and cuproptosis, and the epithelial-to-mesenchymal transition. Narciclasine shows promising efficacy against LUAD and MM spheroid models. These findings warrant further investigation into the mechanisms of action and potential clinical application of Narciclasine for treating thoracic malignancies, offering hope for improved therapeutic options and patient outcomes.<\/jats:p>","DOI":"10.3390\/ijms262010127","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:29:17Z","timestamp":1760711357000},"page":"10127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Narciclasine as a Novel Treatment for Lung Cancer and Malignant Pleural Mesothelioma: Insights from 3D Tumor Spheroid Models"],"prefix":"10.3390","volume":"26","author":[{"given":"Sicong","family":"Jiang","sequence":"first","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serkan","family":"Berkcan","sequence":"additional","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadja","family":"Perriraz-Mayer","sequence":"additional","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-496X","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Triponez","sequence":"additional","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Serre-Beinier","sequence":"additional","affiliation":[{"name":"Division of Thoracic and Endocrine Surgery, Department of Surgery, Faculty of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung Cancer 2020: Epidemiology, Etiology, and Prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: Progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/1078-0432.CCR-23-0251","article-title":"Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial","volume":"30","author":"Parra","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CCO.0000000000000697","article-title":"Malignant pleural mesothelioma: Recent developments","volume":"33","author":"Sinn","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options","volume":"40","author":"Tsao","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103644","DOI":"10.1016\/j.esmoop.2024.103644","article-title":"Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms","volume":"9","author":"Benzerdjeb","year":"2024","journal-title":"ESMO Open"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ramundo, V., Zanirato, G., and Aldieri, E. (2021). The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212216"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the Treatment of Malignant Pleural Mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S2095-4964(16)60237-6","article-title":"Research advances in traditional Chinese medicine syndromes in cancer patients","volume":"14","author":"Ji","year":"2016","journal-title":"J. Integr. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41419-021-03969-1","article-title":"A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"194939","DOI":"10.1016\/j.bbagrm.2023.194939","article-title":"DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer","volume":"1866","author":"Wei","year":"2023","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111381","DOI":"10.1016\/j.biopha.2021.111381","article-title":"Traditional Chinese medicine and lung cancer\u2013From theory to practice","volume":"137","author":"Li","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1097\/CM9.0000000000001141","article-title":"Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer","volume":"133","author":"Su","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S2095-4964(14)60028-5","article-title":"Chemotherapy in conjunction with traditional Chinese medicine for survival of elderly patients with advanced non-small-cell lung cancer: Protocol for a randomized double-blind controlled trial","volume":"12","author":"Zhou","year":"2014","journal-title":"J. Integr. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1038\/s41598-018-26454-w","article-title":"Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation","volume":"8","author":"Weng","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/jcmm.12493","article-title":"Haemanthus coccineus extract and its main bioactive component narciclasine display profound anti-inflammatory activities in vitro and in vivo","volume":"19","author":"Fuchs","year":"2015","journal-title":"J. Cell Mol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/s41598-020-62690-9","article-title":"Narciclasine, an isocarbostyril alkaloid, has preferential activity against primary effusion lymphoma","volume":"10","author":"Gopalakrishnan","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.omto.2021.12.025","article-title":"Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells","volume":"24","author":"Lv","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"174669","DOI":"10.1016\/j.ejphar.2021.174669","article-title":"Narciclasine suppresses esophageal cancer cell proliferation and migration by inhibiting the FAK signaling pathway","volume":"921","author":"Qiu","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"114159","DOI":"10.1016\/j.biopha.2022.114159","article-title":"Narciclasine suppresses oral cancer metastasis by modulating cathepsin B and extracellular signal-related kinase pathways","volume":"158","author":"Shieu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40360-021-00537-3","article-title":"Narciclasine induces autophagy-mediated apoptosis in gastric cancer cells through the Akt\/mTOR signaling pathway","volume":"22","author":"Yuan","year":"2021","journal-title":"BMC Pharmacol. Toxicol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yjmcc.2019.08.001","article-title":"Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2","volume":"135","author":"Bischoff","year":"2019","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e12518","DOI":"10.1111\/cpr.12518","article-title":"Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis","volume":"51","author":"Cao","year":"2018","journal-title":"Cell Prolif."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/med.21253","article-title":"Narciclasine as well as other Amaryllidaceae isocarbostyrils are promising GTP-ase targeting agents against brain cancers","volume":"33","author":"Mathieu","year":"2013","journal-title":"Med. Res. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1593\/neo.07535","article-title":"The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and\/or mitochondrial pathways in cancer cells but not in normal fibroblasts","volume":"9","author":"Dumont","year":"2007","journal-title":"Neoplasia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100008","DOI":"10.1016\/j.bbadva.2021.100008","article-title":"Narciclasine is a novel YAP inhibitor that disturbs interaction between YAP and TEAD4","volume":"1","author":"Kawamoto","year":"2021","journal-title":"BBA Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/omi.2023.0127","article-title":"Decoding Systems Biology of Inflammation Signatures in Cancer Pathogenesis: Pan-Cancer Insights from 12 Common Cancers","volume":"27","author":"Turanli","year":"2023","journal-title":"Omics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s11658-025-00735-5","article-title":"Narciclasine enhances cisplatin-induced apoptotic cell death by inducing unfolded protein response-mediated regulation of NOXA and MCL1","volume":"30","author":"Lee","year":"2025","journal-title":"Cell Mol. Biol. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.4161\/cc.7.17.6460","article-title":"Aurora kinase-A regulates kinetochore\/chromatin associated microtubule assembly in human cells","volume":"7","author":"Katayama","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1038\/s41467-019-13485-8","article-title":"Aurora-A mediated phosphorylation of LDHB promotes glycolysis and tumor progression by relieving the substrate-inhibition effect","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s42255-025-01339-1","article-title":"D-cysteine impairs tumour growth by inhibiting cysteine desulfurase NFS1","volume":"7","author":"Zangari","year":"2025","journal-title":"Nat. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"110996","DOI":"10.1016\/j.biopha.2020.110996","article-title":"Inhibiting RRM2 to enhance the anticancer activity of chemotherapy","volume":"133","author":"Zhan","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1096\/fasebj.4.14.2227213","article-title":"Molecular biology and biochemistry of pyruvate dehydrogenase complexes","volume":"4","author":"Patel","year":"1990","journal-title":"Faseb J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ccell.2025.04.013","article-title":"Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis","volume":"43","author":"Dang","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.cmet.2025.02.008","article-title":"Pyruvate metabolism enzyme DLAT promotes tumorigenesis by suppressing leucine catabolism","volume":"37","author":"Wang","year":"2025","journal-title":"Cell Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103552","DOI":"10.1016\/j.redox.2025.103552","article-title":"Copper in melanoma: At the crossroad of protumorigenic and anticancer roles","volume":"81","author":"Chrzan","year":"2025","journal-title":"Redox Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.bbrc.2020.05.149","article-title":"Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction","volume":"528","author":"Li","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/s12935-020-01689-8","article-title":"RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer","volume":"20","author":"Yang","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wei, X., Li, X., Hu, S., Cheng, J., and Cai, R. (2023). Regulation of Ferroptosis in Lung Adenocarcinoma. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202309.0765.v1"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41420-025-02308-z","article-title":"Targeting ferroptosis: A promising approach for treating lung carcinoma","volume":"11","author":"Wu","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/jacs.8b12123","article-title":"Enantioselective Synthesis of Isocarbostyril Alkaloids and Analogs Using Catalytic Dearomative Functionalization of Benzene","volume":"141","author":"Bingham","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"15049","DOI":"10.1002\/anie.201709712","article-title":"Total Synthesis of Lycoricidine and Narciclasine by Chemical Dearomatization of Bromobenzene","volume":"56","author":"Southgate","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.18632\/oncotarget.28134","article-title":"Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052\/484 spheroids","volume":"12","author":"Gendre","year":"2021","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Colin, D.J., Cottet-Dumoulin, D., Faivre, A., Germain, S., Triponez, F., and Serre-Beinier, V. (2018). Experimental Model of Human Malignant Mesothelioma in Athymic Mice. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19071881"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Mueggler, A., Pilotto, E., Perriraz-Mayer, N., Jiang, S., Addeo, A., B\u00e9dat, B., Karenovics, W., Triponez, F., and Serre-Beinier, V. (2023). An Optimized Method to Culture Human Primary Lung Tumor Cell Spheroids. Cancers, 15.","DOI":"10.21203\/rs.3.rs-3456085\/v1"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/10127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:37:06Z","timestamp":1761021426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/10127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":47,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms262010127"],"URL":"https:\/\/doi.org\/10.3390\/ijms262010127","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}